Pulmonary arterial hypertension(PAH)is a serious and fatal cardiovascular disease that significantly affects patients'quality of life and survival.Current treatments offer some relief but have limited effectiveness and notable side effects.Sotatercept,as a novel drug,modulates the transforming growth factor-β(TGF-β)signaling pathway and shows promising therapeutic effects in PAH.By summarizing the pharmacological mechanisms and clinical research progress of sotatercept in PAH,assessing its application prospects,and analyzing future research directions in the light of current clinical research results,we provide an important perspective for understanding the clinical application of this drug in China,with a view to promoting its promotion and application in China.

Pulmonary arterial hypertension(PAH)is a serious and fatal cardiovascular disease that significantly affects patients'quality of life and survival.Current treatments offer some relief but have limited effectiveness and notable side effects.Sotatercept,as a novel drug,modulates the transforming growth factor-β(TGF-β)signaling pathway and shows promising therapeutic effects in PAH.By summarizing the pharmacological mechanisms and clinical research progress of sotatercept in PAH,assessing its application prospects,and analyzing future research directions in the light of current clinical research results,we provide an important perspective for understanding the clinical application of this drug in China,with a view to promoting its promotion and application in China.